PROTOCOL REVIEW AND MONITORING SYSTEM (Core-010)

方案审查和监测系统(Core-010)

基本信息

  • 批准号:
    9918344
  • 负责人:
  • 金额:
    $ 0.82万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
  • 资助国家:
    美国
  • 起止时间:
  • 项目状态:
    未结题

项目摘要

PROTOCOL REVIEW AND MONITORING SYSTEM ABSTRACT The Protocol Review and Monitoring System (PRMS) is critical to Huntsman Cancer Institute's (HCI) goal to maintain a vibrant clinical research portfolio of scientifically excellent clinical trials for our patients; support the clinical research efforts of our faculty; and improve strategies for cancer detection, diagnosis, treatment, and prevention through our clinical research activities. PRMS functions at HCI are fulfilled by the Clinical Cancer Investigations Committee (CCIC). HCI's robust CCIC enables us to review the scientific merit of proposed clinical studies, evaluate the contribution of proposed protocols to the strategic aims of our Cancer Center, and assess the scientific progress of ongoing studies. The CCIC 1) conducts thorough scientific review of all cancer-related studies performed at HCI, 2) prioritizes research protocols and prevents protocol competition, 3) prioritizes protocols for access to HCI Clinical Trials Office support, 4) evaluates ongoing protocols for continued progress toward accrual goals, 5) reviews and approves protocol amendments, and 6) closes under-accruing trials. Before a study can be presented to the CCIC, it must be submitted to the appropriate Multidisciplinary Disease Group (MDG) for review, approval, and priority rating by the community of HCI physicians in that area. To support HCI's institutional commitment to clinical research, in the current reporting period HCI implemented a Institutional Protocol Development Committee (IPDC) to aid in the development of high quality investigator-intitated trials and a two-stage review process to facilitate rigorous and efficient approval of studies. In stage one review, trials are evaluated by the Feasibility Administrative Review (FAR) committee, which comprises the administrative leadership of the Clinical Protocol and Data Management/Clinical Trials Office. The FAR committee evaluates studies for budget (adequate funding), regulatory, personnel support (clinical research coordinators and research data coordinators), accrual goals, principal investigator (PI) and MDG accrual performance, and completed PI required trainings. Initial review by the FAR committee ensures that studies submitted for stage two CCIC review are strong, with all administrative concerns resolved. In stage two, the CCIC committee, which has broad and extensive expertise in oncology, reviews the scientific merit of new clinical protocols and assesses progress of open studies. The CCIC committee includes representatives from medical oncology, surgical oncology, pediatric hematology-oncology, radiation oncology, biostatistics, pharmacology, pathology, basic science, population sciences, and research nursing, as well as a patient advocate and HCI's CEO/Director Mary Beckerle, PhD, as an ex-officio member.
协议审查和监测系统 摘要 方案审查和监测系统(PRMS)对于亨斯迈癌症研究所(HCI)的目标至关重要 为我们的患者维护充满活力的临床研究组合,包括科学上优秀的临床试验;支持 我们教员的临床研究努力;以及改进癌症检测、诊断、治疗和治疗的策略 通过我们的临床研究活动进行预防。人机界面的PRMS功能是由临床癌症实现的 调查委员会(CCIC)。HCI强大的CCIC使我们能够审查建议的 临床研究,评估拟议方案对我们癌症中心战略目标的贡献,以及 评估正在进行的研究的科学进展。 CCIC 1)对在HCI进行的所有与癌症相关的研究进行彻底的科学审查,2) 确定研究协议的优先顺序并防止协议竞争,3)确定访问HCI的协议的优先顺序 临床试验办公室支持,4)评估持续进展以实现应计目标的正在进行的方案,5) 审查和批准方案修正案,以及6)结束累积不足试验。在一项研究可以 提交给CCIC,必须提交给适当的多学科疾病小组(MDG) 由该领域的HCI医生社区进行审查、批准和优先评级。 在本报告所述期间,为支持HCI对临床研究的机构承诺,HCI 实施了机构礼仪开发委员会(IPDC),以帮助高质量的发展 调查员发起的试验和两个阶段的审查程序,以促进严格和有效地批准 学习。在第一阶段审查中,试验由可行性行政审查委员会(FAR)进行评估, 它包括临床方案和数据管理/临床试验的行政领导 办公室。FAR委员会评估预算(充足资金)、监管、人事支持等方面的研究 (临床研究协调员和研究数据协调员)、应计目标、首席研究员(PI)和 千年发展目标绩效考核,完成绩效指标要求的培训。FAR委员会的初步审查确保 提交CCIC第二阶段审查的研究是强有力的,所有行政问题都得到了解决。 在第二阶段,在肿瘤学方面拥有广泛和广泛专业知识的CCIC委员会审查 新的临床方案的科学价值和评估开放研究的进展。CCIC委员会包括 来自内科肿瘤学、外科肿瘤学、儿科血液肿瘤学、放射肿瘤学、 生物统计学、药理学、病理学、基础科学、人口科学、研究护理学以及 患者权益倡导者和HCI的首席执行官/主任Mary Beckerle博士,作为当然成员。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Wallace Lovell Akerley其他文献

Wallace Lovell Akerley的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Wallace Lovell Akerley', 18)}}的其他基金

Imaging Diagnostics and Therapeutics Program
影像诊断和治疗项目
  • 批准号:
    8180708
  • 财政年份:
    2010
  • 资助金额:
    $ 0.82万
  • 项目类别:
Clinical Trials Office Shared Resource
临床试验办公室共享资源
  • 批准号:
    8180957
  • 财政年份:
    2010
  • 资助金额:
    $ 0.82万
  • 项目类别:
OXIGENE CA4P-212 FOR SUBJECTS WITH ADVANCED IMAGEABLE MALIGNANCIES
OXIGENE CA4P-212 适用于患有晚期可成像恶性肿瘤的受试者
  • 批准号:
    7718506
  • 财政年份:
    2008
  • 资助金额:
    $ 0.82万
  • 项目类别:
OXIGENE CA4P-212 FOR SUBJECTS WITH ADVANCED IMAGEABLE MALIGNANCIES
OXIGENE CA4P-212 适用于患有晚期可成像恶性肿瘤的受试者
  • 批准号:
    7604964
  • 财政年份:
    2007
  • 资助金额:
    $ 0.82万
  • 项目类别:
SUBJECTS WITH ADVANCED IMAGEABLE MALIGNANCIES
患有晚期可成像恶性肿瘤的受试者
  • 批准号:
    7376474
  • 财政年份:
    2006
  • 资助金额:
    $ 0.82万
  • 项目类别:
Protocol Review and Monitoring System
方案审查和监控系统
  • 批准号:
    10152553
  • 财政年份:
    1997
  • 资助金额:
    $ 0.82万
  • 项目类别:
Protocol Review and Monitoring System
方案审查和监控系统
  • 批准号:
    10388139
  • 财政年份:
    1997
  • 资助金额:
    $ 0.82万
  • 项目类别:
Protocol Review and Monitoring System
方案审查和监控系统
  • 批准号:
    10611366
  • 财政年份:
    1997
  • 资助金额:
    $ 0.82万
  • 项目类别:
Clinical Protocol and Data Management
临床方案和数据管理
  • 批准号:
    8853749
  • 财政年份:
    1997
  • 资助金额:
    $ 0.82万
  • 项目类别:
PROTOCOL REVIEW AND MONITORING SYSTEM (Core-010)
方案审查和监测系统(Core-010)
  • 批准号:
    9918343
  • 财政年份:
  • 资助金额:
    $ 0.82万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 0.82万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 0.82万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 0.82万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 0.82万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 0.82万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 0.82万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 0.82万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 0.82万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 0.82万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 0.82万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了